LP
MNPR icon

Longaeva Partners’s Monopar Therapeutics MNPR Stock Holding History

Longaeva Partners’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17M Buy
+55,834
New +$3.46M 0.11% 171

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Longaeva Partners's MNPR Position: Q2 2026 in Review

Longaeva Partners opened a new position in Monopar Therapeutics (MNPR) in Q2 2026: 55,834 shares worth $5.17M. The stake represents 0.11% of the portfolio and ranks #171 among its holdings.

96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Longaeva Partners held 55,834 shares of Monopar Therapeutics worth $5.17M as of Q2 2026.
  • Monopar Therapeutics was a new Longaeva Partners position in Q2 2026.
  • Monopar Therapeutics made up 0.11% of Longaeva Partners's portfolio in Q2 2026, its #171 holding.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.